The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | ABVD vs. escBEACOPP in HL: a 10-year study
In the UK, escalated BEACOPP (escBEACOPP) was introduced as an alternative to ABVD for the treatment of advanced-stage Hodgkin lymphoma (HL). Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the 10-year retrospective study of ABVD vs. escBEACOPP in HL patients in both trial (RATHL; Trial: RATHL, NCT00678327) and non-trial settings. Dr Follows expresses excitement at presenting the data at this year’s American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
